| Company/Division name | PharmaEssentia |
| Parent company | PharmaEssentia |
| Type of work | Manufacturing |
| Reshoring category: | Foreign Direct Investment |
| Total number of jobs (added or to be added): | 100 |
| Year reshoring announced: | 2026 |
| Domestically, the work will be done: | In-house |
| Capital investment ($): | 46 |
| Country(ies) from which reshored: | Taiwan, Province of China |
| State(s) reshored to: | PR |
| If relevant, work nearshored to: | - |
| Industry(ies): | Chemicals |
| Product(s) reshored | Biopharma, Besremi |
| What domestic positive factors made reshoring more attractive? | Eco-system synergies, Proximity to customers/market |
